Tagged geovax

Press Release

GeoVax Trial Results Establish a New Benchmark for Preventative HIV Vaccine Model

 Non Human Primate Study Demonstrates Unprecedented 70% Prevention of Infection Read More
Press Release

GeoVax Launches Second Clinical Site To Test The Therapeutic Benefit of HIV Vaccine

 University of Alabama at Birmingham to Serve as Second Site for Ongoing Clinical Trial Read More
Press Release

GeoVax Awarded Federal Grant Under The Qualifying Therapeutic Discovery Project Program

 The grant was awarded following GeoVax's submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services. Read More
Press Release

One Company Aims to Repurpose a Smallpox Vaccine to Battle HIV

 Because of the difficulty raising antibodies that are capable of totally blocking natural HIV infections, the GeoVax vaccine approach has focused on raising cellular immune responses in addition to antibodies. Read More
Press Release

GeoVax Labs, Inc. Announces Six Month 2010 Financial Results and Provides Operational Update

 GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm (the "Company") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results and provided an update. Read More
Press Release

Newly Discovered Antibodies May Boost AIDS Vaccine Research

 GeoVax is developing a vaccine that presents the natural form of HIV envelope proteins to the immune system on virus-like particles with the envelope proteins present in clusters of three, a confirmation known as trimers. Read More
Press Release

Early Diagnosis and Treatment for HIV Has Life-Saving Impact on Patients

 Since 1995, National HIV Testing Day has united organizations across the nation every June 27th to promote the early diagnosis of HIV. Read More